Opinion|Videos|January 17, 2025

CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

Author(s)Ajai Chari, MD, Anupama Kumar, MD, Darren Pan, MD

Panelists discuss how CAR T-cell therapy involves engineering a patient’s T cells to target cancer cells. The process includes cell collection, genetic modification, expansion, and reinfusion and streamlines the process with integrated workflows. Bridging therapy is provided in-house to treat patients awaiting CAR-T infusion.

Episodes in this series

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

Video content above is prompted by the following:

Could you explain how CAR T-cell therapy works and describe the treatment process?
Do you consider CAR T-cell therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
Do you send patients back to the community center or does it happen in-house?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

$Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.$

October 9th, 2026

Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM

Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.

How Long-Term Data Reinforce Daratumumab Use in NDMM: © Giovanni Cancemi - stock.adobe.com

October 9th, 2026

How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?

Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

October 8th, 2026

How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

$Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.$

October 8th, 2026

Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma

Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.

$Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.$

October 7th, 2026

Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma

Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.

$Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.$

October 6th, 2026

Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy

Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

September 29th, 2026

Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Trending on CancerNetwork

FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer

How Emory Became the First Adopter of the Liberty Endovascular Robotic System

Building out a Radiopharmaceuticals Program in Oncology Care

Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression

Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma